Literature DB >> 9437477

The IMPROVE study: background and study design. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers.

B L Carter1, D C Malone, R J Valuck, D J Barnette, C D Sintek, S J Billups.   

Abstract

An ongoing study of the impact of ambulatory care clinical pharmacists on patient outcomes at selected Veterans Affairs medical centers (VAMCs) is described. The IMPROVE (Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers) study will examine the effects of referring patients at high risk for drug-related problems to a pharmacist-managed monitoring program. Nine study sites from diverse geographic locations and small and large urban areas have been selected. Investigators visited each site to evaluate the structure of care, observe pharmacist-patient interactions, and assess the level and documentation of pharmacists' activities. A coordinating center will collect and process patient-specific data from the study sites to identify high-risk patients. It is expected that 500 intervention patients and 500 control patients from the nine VAMCs will complete all portions of the study. Intervention patients will be scheduled for medication assessments by ambulatory care pharmacists and will be monitored by pharmacists for at least 12 months. The coordinating center will track refill histories for intervention patients. Investigators will assess the activities performed by ambulatory care pharmacists to determine predictors of successful patient outcomes. The two groups will be compared with respect to change from baseline in quality of life and satisfaction with health care providers. A cost-benefit analysis will be undertaken to determine the impact of pharmaceutical care relative to total patient care costs. The main outcome results of the IMPROVE study are expected to be available in 1999. The IMPROVE project will be the first study of the impact of ambulatory care clinical pharmacists on patient outcomes.

Entities:  

Mesh:

Year:  1998        PMID: 9437477     DOI: 10.1093/ajhp/55.1.62

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  5 in total

Review 1.  Pharmaceutical care programmes for the elderly: economic issues.

Authors:  Grainne E Crealey; Ian K Sturgess; James C McElnay; Carmel M Hughes
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

2.  The Iowa Continuity of Care study: Background and methods.

Authors:  Barry L Carter; Karen B Farris; Paul W Abramowitz; David B Weetman; Peter J Kaboli; Jeffrey D Dawson; Paul A James; Alan J Christensen; John M Brooks
Journal:  Am J Health Syst Pharm       Date:  2008-09-01       Impact factor: 2.637

Review 3.  Comparison of drug-related problem risk assessment tools for older adults: a systematic review.

Authors:  Emmi Puumalainen; Marja Airaksinen; Sanni E Jalava; Timothy F Chen; Maarit Dimitrow
Journal:  Eur J Clin Pharmacol       Date:  2019-12-10       Impact factor: 2.953

Review 4.  Cost of pharmacological care of the elderly: implications for healthcare resources.

Authors:  Ciaran O'Neill; Carmel M Hughes; James Jamison; Anna Schweizer
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 5.  Repeat prescribing: scale, problems and quality management in ambulatory care patients.

Authors:  Peter A G M De Smet; Maaike Dautzenberg
Journal:  Drugs       Date:  2004       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.